

SUGAMMADEX

- je snížení ceny důvodem pro jeho používání bez monitorace nervosvalové blokády?

Satelitní symposium ČSARIM s podporou společnosti MEDISTA
Aktuální otázky monitorace a antagonizace nervosvalové blokády

Čtvrtek 19. 9. 2024, 16:30–17:30

Sál E1b, Pávilon E, Brněnské výstaviště

1. Svalová relaxace – proč to je stále aktuální téma oboru? - Vladimír Černý
2. Metody monitorace svalové relaxace – update 2024 – Tomáš Tyll
3. Reziduální nervosvalová blokáda – update 2024 – Michael Stern
4. Sugamadex – je snížení ceny důvodem pro jeho používání bez monitorace nervosvalové blokády? – Jan Bláha
5. Kdy sugamadex nefunguje? – Michal Horáček
6. Jak lze definovat správnou klinickou praxi na základě současné evidence? – Vladimír Černý
7. Diskuze

JAN BLÁHA

KLINIKA ANESTEZIOLOGIE, RESUSCITACE A INTENZIVNÍ MEDICÍNY 



1. LÉKAŘSKÁ
FAKULTA
Univerzita Karlova




VŠEOBECNÁ FAKULTNÍ
NEMOCNICE V PRAZE

jan.blaha@vfn.cz



Tak kdysi
možná snad ...


... ale to tu byli
jiní šibři :)



KARIM



Předvánoční setkání
s **BRIDIIONEM**
10. prosince 2012 - 17:00
Hôtel Maximus Resort



bridion
sugammadex
Předvídatelný. Kompletní. Rychlý.

COST nebo BENEFIT ?

Jan Bláha
Klinika anesteziologie, resuscitace a intenzivní medicíny
1. lékařská fakulta Univerzity Karlovy v Praze
Všeobecná fakultní nemocnice v Praze

**CHIRURGIE, ANESTEZIE
NEBO PERIOPERAČNÍ MEDICÍNA**



JAN BLÁHA
Klinika anesteziologie, resuscitace a intenzivní medicíny
1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze

bridion
sugammadex
Předvídatelný. Kompletní. Rychlý.

Jan Bláha
Klinika anesteziologie, resuscitace a intenzivní medicíny
1. lékařská fakulta Univerzity Karlovy v Praze
Všeobecná fakultní nemocnice v Praze

**SPOLEČNÉ ZÁJMY
NEBO SPOLEČNÉ CÍLE?**



JAN BLÁHA
Klinika anesteziologie, resuscitace a intenzivní medicíny
1. lékařská fakulta Univerzity Karlovy v Praze
Všeobecná fakultní nemocnice v Praze

**PERIOPERAČNÍ PÉČE
z pohledu anesteziologa**

27.4.2018
JAN BLÁHA
Klinika anesteziologie, resuscitace a intenzivní medicíny
1. lékařská fakulta Univerzity Karlovy v Praze
Všeobecná fakultní nemocnice v Praze

**CHIRURGIE, ANESTEZIE
PERIOPERAČNÍ MEDICÍNA**

JAN BLÁHA
Klinika anesteziologie, resuscitace a intenzivní medicíny
1. lékařská fakulta Univerzity Karlovy v Praze
Všeobecná fakultní nemocnice v Praze

**(NE)BEZPEČNÁ
ANESTEZIE**

JAN BLÁHA
Klinika anesteziologie, resuscitace a intenzivní medicíny
1. lékařská fakulta Univerzity Karlovy v Praze
Všeobecná fakultní nemocnice v Praze

**BRIDIION
Právní souvislosti**

JAN BLÁHA
Klinika anesteziologie, resuscitace a intenzivní medicíny
1. lékařská fakulta Univerzity Karlovy v Praze
Všeobecná fakultní nemocnice v Praze

**CHIRURGIE, ANESTEZIE
PERIOPERAČNÍ MEDICÍNA**

19.6.2020
JAN BLÁHA
Klinika anesteziologie, resuscitace a intenzivní medicíny
1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze

**DEEP NEUROMUSCULAR BLOCK
(EXPERTS' OWN EXPERIENCE)**

28.2.2020
JAN BLÁHA
Klinika anesteziologie, resuscitace a intenzivní medicíny
1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze

2007

SUGAMMADEX

Obk. 1. Enkapsulace molekuly rocuronia prodráží molekulou sugammadexu v poměru 1 : 1.

Raft J. et al. 51^e congrès national d'anesthésie et de réanimation, France.

28.2.2020 Kojipák nemocnice Liberec, a.s.

The salient characteristics of RSI were delineated by Stept and Safar in 1970 [3].

- Preoxygenation
- Predetermined doses of thiopental and SCH
- Cricoid force
- Avoidance of ventilation by bag and mask
- Tracheal intubation

Sharp LM, Levy DM. Current Opinion in Anaesthesiology 2009, 22:357-361

28.2.2020 Kojipák nemocnice Liberec, a.s.

The Response of Newborns to Succinylcholine and d-Tubocurarine

Leonard F. Walts, M.D.,* and John B. Dillon, M.D.†

Anesthesiology, 1969 Jul;31(1):85-8.

Results

Mean age of the 60 adult patients was 41 years. The group given succinylcholine received an average of 68 mg (range 54–83) of drug. All patients had 100 per cent depression in twitch force. Recovery times to 10, 50 and 90 per cent of control values averaged 7.0, 8.5, and 10 minutes, respectively.

28.2.2020 Kojipák nemocnice Liberec, a.s.

0,6 mg/kg

1 mg/kg

Figure 2 Kaplan-Meier curve of the probability of the completion of the endotracheal intubation sequence including succinylcholine or rocuronium as the neuromuscular blocking drug. Time 0 denotes the beginning of the injection of the induction drug propofol. The endotracheal intubation sequence was defined to be completed upon the first appearance of end-tidal carbon dioxide after intubation. Curves differ significantly ($P < 0.0001$; logrank test).

Sluga M et al. Anesth Analg 2005;101:1356–61

Figure 2 Intubating times. Kaplan-Meier curve of the probability of the completion of the endotracheal intubation sequence including succinylcholine or rocuronium in patients successfully intubated in the first attempt. The x-axis denotes the time interval after the beginning of the injection of the induction drug. The intubation sequence was defined to be completed upon the first appearance of end-tidal carbon dioxide after intubation.

Stephan C Marsch, et al. Crit Care. 2011;15(4):R199-R199

28.2.2020 Kojipák nemocnice Liberec, a.s.

Desaturation following rapid sequence induction using succinylcholine vs. rocuronium in overweight patients

L. Tian¹, S. Li¹, S. Zhou², H. Ma¹ and Z. Wang²

Department of Anesthesiology and Pain Management, Shanghai Tenth People's Hospital, Shanghai Jiaotong University, Shanghai, China

Background: Rapid sequence induction may be associated with hypoxemia. The purpose of this study was to investigate the possible difference in desaturation during rapid sequence induction in overweight patients using either succinylcholine or rocuronium.

Methods: Sixty patients with a body mass index (BMI) between 30 and 40 kg/m² American Society of Anesthesiologists grade III or IV were randomly divided into succinylcholine group and rocuronium group after a propofol premedication. Patients received rapid sequence induction with succinylcholine 1.5 mg/kg or rocuronium 1.0 mg/kg, and propofol 2 mg/kg. End-tidal oxygen saturation (SpO₂) was monitored with a spot-reading pulse oximeter. The median SpO₂ 5 min after induction was defined as 95%. We assessed the times when oxygen saturation reached 95%, 90%, 85%, and 80%. After a propofol premedication, the time to reach 95% SpO₂ was defined as the time from intubation of the rocuronium group to the time from intubation of the succinylcholine group.

Results: The median SpO₂ 5 min after rocuronium induction (95.0%) was significantly higher than succinylcholine induction (92.0%) ($P < 0.001$). The median SpO₂ 5 min after rocuronium induction (95.0%) was significantly higher than succinylcholine induction (92.0%) ($P < 0.001$). The median SpO₂ 5 min after rocuronium induction (95.0%) was significantly higher than succinylcholine induction (92.0%) ($P < 0.001$). The median SpO₂ 5 min after rocuronium induction (95.0%) was significantly higher than succinylcholine induction (92.0%) ($P < 0.001$).

Conclusion: Succinylcholine was associated with a significantly lower SpO₂ 5 min after induction compared with rocuronium in overweight patients.

© 2009 The Author
Journal compilation © 2009 The Author
Anaesthesia © 2009 Blackwell Publishing Ltd

Figure 1 Time to reach SpO₂ of 95% during apnoea following induction of anaesthesia with lidocaine/fentanyl/propofol/rocuronium (Group R), lidocaine/fentanyl/propofol/succinylcholine (Group S), or propofol/succinylcholine (Group SO).

28.2.2020 Kojipák nemocnice Liberec, a.s.

Figure 4. Panel A shows the recovery of the twitch height and train-of-four (TOF) ratio after administration of 1.2 mg/kg rocuronium followed 3 min later by 16 mg/kg sugammadex, both given IV. Recovery to a first twitch height (T1) of 90% and a TOF ratio of 0.94 occurred 110 s later. The onset-to-peak time with this sequence (i.e., the time from the end of the injection of rocuronium to a T1 recovery to 90%) was 4 min 47 s. Panel B shows the effects of administering 1.0 mg/kg succinylcholine (Sch) with spontaneous recovery to a T1 of 90% occurring after 9 min and 23 s.

Naugib M. Anesth Analg 2007;104:575–81

28.2.2020 Kojipák nemocnice Liberec, a.s.

RESIDUÁLNÍ NMB...

Umím to
i bez toho...

Myth #2

IF YOU KNOW THE PHARMACOKINETICS OF MUS-
CLE RELAXANTS, NEUROMUSCULAR MONITOR-
ING AND REVERSAL DRUGS ARE NOT NECESSARY

Myth #3

THE CLINICAL EFFECTS OF POST-OPERATIVE RE-
SIDUAL CURARIZATION (PORC) IS COMPLETE-
LY OVERRATED

On to až
takový problém
není...

The RECITE Study: A Canadian Prospective, Multicenter Study of the Incidence and Severity of Residual Neuromuscular Blockade

Louis-Philippe Fortier, MSc, MD, FRCPC,* Dolores McKeen, MD, MSc, FRCPC,† Kim Turner, BScPhm, MSc, MD, FRCPC,‡§ Étienne de Médicis, MD, FRCPC,|| Brian Warriner, MD, FRCPC,¶ Philip M. Jones, MD, FRCPC, MSc,#** Alan Chaput, BScPhm, PharmD, MD, MSc, FRCPC,†† Jean-François Pouliot, PhD,‡‡ and André Galarneau, MSc, PhD‡‡

BACKGROUND: Postoperative residual neuromuscular blockade (NMB), defined as a train-of-

The RECITE Study




Figure 2. Incidence of residual neuromuscular blockade. nTOFr = normalized train-of-four ratio; TOFr = nonnormalized train-of-four ratio.

CONCLUSIONS: Residual paralysis is common at tracheal extubation and PACU arrival, despite qualitative neuromuscular monitoring and the use of neostigmine. More effective detection and management of NMB is needed to reduce the risks associated with residual NMB. (Anesth Analg 2015;XXX:00-00)

Table 2 Selected reports of postoperative residual paralysis, 2006–2016.


Study	Intermediate-acting NMBA	Reversal	TOF Threshold	Monitoring modality	Residual paralysis	Comments
Cammu et al. [26]	Atrac/Cis/Miv/Roc Outpatients Inpatients	In 26% In 25%	0.9	Clinical (49% of cases)	38% 47%	One of 320 inpatients required re-intubation in PACU; Subjective assessment did not decrease incidence of residual paralysis
Maybauer et al. [88]	Cis Roc	None	0.9 0.9	AMG AMG	57% 44%	Variability in duration of action of Roc greater than Cisatrac AMG lowers RNMB risk
Murphy et al. [89]	Roc	Yes	0.9	AMG Subjective	5% 30%	Less RNMB with Cis
Butterly et al. [14]	Vec/Cis	Yes	0.9	Subjective	22%	21% of patients with RNMB required airway support
Yip et al. [90]	Atrac/Vec/Roc	In 65%	0.9	Subjective Not reported	31%	
Murphy et al. [7]	Roc	Yes	0.9 0.9	AMG Subjective	15% 50%	AMG monitoring lowers RNMB
Cammu et al. [91]	Atrac/Roc/Miv	None Neo SGX	0.9	Subjective (38% of cases)	15% 15% 2%	Body mass index was an independent predictor of desaturation in PACU
Kumar et al. [92]	Vec Atrac Roc	Yes in 100%	0.9	Not performed	66% 60% 46%	RNMB resulted in reductions in forced vital capacity and peak expiratory flow
Norton et al. [93]			0.9		30%	CRE present in 51% with RNMB
Esteves et al. [94]	Atrac/Cis/Roc/Vec	Yes (67% of patients)	0.9	Subjective	26%	Incomplete recovery more frequent after reversal than no reversal (31% vs. 17%)
Kotake et al. [17]	Roc	None Neo SGX	0.9	Clinical	13% 24% 4%	RNMB as high as 9% with SGX without monitoring
Pietraszewski et al. [95]	Roc	None	0.9	Not used	44%	Incidence of RNMB was 44% in elderly and 20% in young patients
Fortier et al. [96]	Roc	Yes	0.9	Optional	64%	Incidence of RNMB was 56% on PACU arrival
Xara et al. [97]	NMBAs used in 66% of patients	Yes	0.9	Optional	18%	CRE more common (46%) in patients with RNMB
Ledowski et al. [98]	Atrac/Roc/Vec	Yes (48% of patients)	0.9	Optional (used in 23% of patients)	28%	RNMB after neo reversal was twice as high as no reversal in paediatric patients
Brueckmann et al. [99]	Roc	Yes-Neo Yes-SGX	0.9 0.9	Subjective	43% 0%	OR discharge shorter in SGX-treated patients
Batistaki et al. [18]	Roc/Cis	Yes-Neo Yes-SGX	0.9 0.9	Clinical	14.6% 9.5%	Female gender and co-morbidities increased incidence of RNMB

NMBA, neuromuscular blocking agent; TOF, train-of-four; RNMB, residual neuromuscular block; Atrac, atracurium; Cis, cisatracurium; Vec, vecuronium; Roc, rocuronium; Miv, mivacurium; PACU, post-anaesthesia care unit; AMG, acceleromyography; CRE, critical respiratory events; SGX, sugammadex; OR, operating room.




vs.






bridion 100 mg/ml
2 ml x 200 mg




bridion 100 mg/ml
2 ml x 200 mg

2 500 Kč



2 mg/kg

2 000 Kč



1 mg/kg

1 000 Kč

Sbírka zákonů č. 372 / 2011

ČESKÁ REPUBLIKA

ZÁKON
ze dne 6. listopadu 2011
o zdravotních službách a podmínkách jejich poskytování
(zákon o zdravotních službách)

Právní předpis se usnesl na tomto zákoně České republiky:

Článek 2

Člásek 2 odst. 1 písm. a) stanoví, že zdravotní služby lze poskytovat pouze s jeho svobodným a informovaným souhlasem pacienta, pokud není ustanováno jinak.

(5) Zdravotní služby lze poskytovat pouze s jeho svobodným a informovaným souhlasem pacienta, pokud není ustanováno jinak.

(2) Pacient má právo na poskytování zdravotních služeb na náležité odborné úrovni.

Všeobecná fakultní nemocnice v Praze

Depozitářský postup pro použití sugammadexu

1. Účel a oblast platnosti dokumentu


2. Popis a účel

3. Odpovědnosti a pravomoci

4. Postup (praxe)

5. Stanovení klinické situace (viz schéma, kap. 4.3)


6. Neuronální blok monitorovaný s TOF a PTC



PROBLEM SOLVED

SUGAMMADEX

- je snížení ceny důvodem pro jeho používání bez monitorace nervosvalové blokády?



**PROČ DÁVÁME
SVALOVÁ
RELAXANCIA?**



**ABYCHOM
ZAJISTILI BEZPEČNOST
VÝKONU ...**

**ABYCHOM
PACIENTA PROVEDLI
OPERACÍ**

**ABYCHOM
ZAJISTILI HEMODYNA-
MICKOU STABILITU
PACIENTA...**

**ABYCHOM
PACIENTOVI ZAJISTILI
ANALGEZII ...**

**ABYCHOM
OHLÍDALI CHIRURGY**

**PROČ DÁVÁME
ANESTEZII ?**

**ABY CHIRURG
MOHL BEZPEČNĚ
OPEROVAT**



**ZAJIŠTĚNÍ DC
INTUBACÍ**


**OPTIMALIZACE
UPV**

**PROČ DÁVÁME
SVALOVÁ
RELAXANCIA?**

**DOBŘE
CHIRURGICKÉ
PODMÍNKY**



Deep Neuromuscular Block Improves Surgical Conditions during Bariatric Surgery and Reduces Postoperative Pain: A Randomized Double Blind Controlled Trial





Influence of deep relaxation on surgical conditions. Leiden-surgical rating scale (L-SRS) values of patients during a deep neuromuscular block (target PTC 2–3; orange, n = 50) and during a moderate neuromuscular block (target TOF 1–2; blue, n = 50). Values are mean (95% confidence interval) with confidence intervals derived from bootstrap analyses. * Mann-Whitney-U test p < 0.01 versus moderate block.
doi:10.1371/journal.pone.0167907.g002



Score	Interpretation	Treatment group	
		Moderate block	Deep block
5	Optimal conditions	10%	70%
4	Good conditions	20%	20%
3	Acceptable conditions	55%	10%
2	Poor conditions	10%	0%
1	Extremely poor conditions	5%	0%

Discussion: We aim to show that under the right conditions the perceived opposing goals of surgeons and anesthesiologists (optimal surgical conditions vs. optimal postoperative conditions) may be met without compromise to either.

Boon et al. *Trials*. 2013 Mar 1;14:63





ORIGINAL ARTICLE

Surgical conditions with rocuronium versus suxamethonium in cesarean section: a randomized trial

J. Bláha,^{a,†} P. Nosková,^{a,†} K. Hlinecká,^b V. Krakovská,^c V. Fundová,^a T. Bartošová,^a
 P. Michálek,^a M. Strítěský^a

^aDepartment of Anesthesiology, Resuscitation and Intensive Medicine, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic




Table 2 Times from induction of anesthesia to end of surgery; and induction characteristics.

	Rocuronium group		Suxamethonium group		Difference in means	P-value
	Mean	Median	mean	median		
Induction – delivery interval (s)	268.4 (72.9)	265 (223–330)	275.6 (63.4)	267 (239–400)	–7.2 (–39.5 to 19.3)	0.62
Induction – intubation interval (s)	105.8 (33.7)	108 (77–134)	67.6 (32.1)	63 (50–123)	38.2 (24.4 to 52.0)	<0.001
Incision – delivery interval (s)	146.6 (68.3)	130 (99–179)	196.2 (50.7)	201 (167–277)	–49.7 (–74.8 to –24.4)	0.0002
Intubation – incision interval (min)	15.8 (6.9)	15 (4–42)	11.7 (6.4)	10 (3–29)	4.1 (0.4 to 7.8)	0.061
Length of surgery (min)	39.3 (8.9)	39 (27–53)	39.4 (9.6)	38 (26–54)	0.1 (–4.0 to 3.8)	0.976
End of surgery to extubation (min)	5.2 (4.6)	4 (0–13)	8.8 (5.8)	8 (2–19)	–3.5 (–5.8 to 1.4)	0.002
SRSD (points)	3.73 (0.53)	3.7 (3–4)	2.77 (0.55)	3 (2–4)	1.0 (–0.01 to 0.20)	<0.001
Blood loss (mL)	533 (79)	500 (500–600)	538 (98)	500 (500–650)	–5 (–38 to 28)	0.859
Thiopental (mg/kg)	4.7 (0.16)	4.7 (4.5–5.1)	4.7 (0.21)	4.7 (4.5–5.3)		0.471
Muscle relaxant dose (mL/kg)	0.092 (0.01)	0.093 (0.090–0.106)	0.095 (0.00)	0.094 (0.09–0.106)		0.072
Muscle relaxant dose (mg/kg)	0.55 (0.05)	0.56 (0.54–0.65)	0.95 (0.04)	0.94 (0.9–0.11)		0.177

Data are presented as mean (SD) or median (range). Difference between the groups is expressed as median (95% confidence interval). SRSD: Surgical rating scale for delivery.

čas incize - porod


**TEĎ JSEM
PŘIDAL ...**

**TEĎ NA KONCI ?
TO VÍŠ ŽE JO...!**


👎!💣🎯☠️👉♦️!!!

TLAČÍ !





==



Is Anesthesia Dangerous?

André Gottschalk, Hugo Van Aken, Michael Zenz, Thomas Standl

TABLE 2

Association between anesthesia-related deaths and age or patients' ASA status (adapted from [5])

	Mortality/100 000 anesthesiological procedures	95% confidence interval
Age		
0–7 years	0.6	0.12–3.2
8–15 years	1.2	0.3–3.2
16–39 years	0.52	0.24–0.93
40–75 years	5.2	2.7–8.1
≥ 75 years	21	8.3–34
ASA classification		
ASA I	0.4	0.12–0.81
ASA II	5	1.6–9.1
ASA III	27	12–44
ASA IV	55	1.1–130


Gottschalk „Is anesthesia dangerous? Dtsch Arztebl Int 2011; 108(27): 469–74.

Anesthesiology 2009; 110:759–65

Copyright © 2009, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

Epidemiology of Anesthesia-related Mortality in the United States, 1999–2005

Guohua Li, M.D., Dr.P.H.,* Margaret Warner, Ph.D.,† Barbara H. Lang, B.S.,‡ Lin Huang, M.S.,§ Lena S. Sun, M.D.||



Epidemiology of Anesthesia-related Mortality in the United States, 1999–2005


Guohua Li, M.D., Dr.P.H.,* Margaret Warner, Ph.D.,† Barbara H. Lang, B.S.,‡ Lin Huang, M.S.,§ Lena S. Sun, M.D.||

Table 2. Anesthesia-related Deaths by Type of Complication, United States, 1999–2005

Type of Complication	Number of Deaths	%
Complications of anesthesia during pregnancy, labor, and puerperium	79	3.6
Cardiac complications	60	2.7
Overdose of anesthetics	1,030	46.6
Inhaled anesthetics	233	10.5
Intravenous anesthetics	419	19.0
Other and unspecified general anesthetics	254	11.5
Local anesthetics	86	3.9
Unspecified anesthetics	38	1.7
Adverse effects of anesthetics in therapeutic use	940	42.5
Opioids and related analgesics	439	19.9
Benzodiazepines	42	1.9
Other and unspecified general anesthetics	40	1.8
Local anesthetics	137	6.2
Unspecified anesthetics	257	11.6
Other complications of anesthesia	162	7.3
Malignant hyperthermia	22	1.0
Failed or difficult intubation	50	2.3
Total	2,211	100.0

ICD-10 = *International Classification of Diseases*, 10th Revision.

Figure 5. Graphs show the observed T₄/T₁ twitch ratio upon spontaneous neuromuscular blockade reversal following rocuronium administration, conditioned on administered dose and use of sevoflurane anaesthesia (n = 59).



Br J Clin Pharmacol. 2011 September; 72(3): 415–433.

The Prolonged Duration of Rocuronium in Chinese Patients

Linda M. Collins, MB, BCh, BAO, FFARCSI*, Joan C. Bevan, MD, FRCA†, David R. Bevan, MB, MRCP, FRCA*, Giselle C. P. Villar, MD†, Raymond Kahwaji, MD, FRCPC†, Michael F. Smith, MD, FRCPC†, and François Donati, PhD, MD, FRCPC‡

Departments of Anesthesia, *Vancouver General Hospital and †British Columbia's Children's Hospital, University of British Columbia, Vancouver, British Columbia, and ‡Université de Montréal, Montréal, Québec, Canada

We compared the potency and duration of action of rocuronium in Chinese and Caucasian patients during general anesthesia. Thirty-six women (18 Caucasian and 18 Chinese) and 36 children (18 Caucasian and 18 Chinese) were evaluated during the administration of propofol/fentanyl anesthesia. Patients in each age group were randomized into three subgroups to receive single doses of 0.06, 0.12, or 0.18 mg/kg rocuronium (adults) or 0.12, 0.18, or 0.24 mg/kg rocuronium (children). Neuromuscular blockade was assessed by electromyography of the adductor pollicis after train-of-four (TOF) stimulation of the ulnar nerve. Dose response curves were constructed when maximum neuromuscular depression of the first twitch of the train (T_1) was obtained. A second bolus dose of rocuronium was then administered to a total dose of 0.6 mg/kg. The times of spontaneous recovery to T_1 10%, 25%, and 90%

of control and to TOF 0.25, 0.50, and 0.70 were recorded. For both adults and children, recovery occurred later in Chinese than in Caucasian patients ($P < 0.05$ for T_1 of 10%, 25%, 75%, and 90% and TOF to 0.7). The 50% effective dose was smaller in Chinese adults (125 ± 63 vs $159 \pm 66 \mu\text{g}/\text{kg}$) and Chinese children (171 ± 43 vs $191 \pm 46 \mu\text{g}/\text{kg}$) than in Caucasian adults and children, but the difference was not statistically significant. In adults, time to 25% T_1 recovery was 43 ± 13 min in Chinese patients and 33 ± 10 min in Caucasian patients ($P < 0.05$). The corresponding values were more rapid for children: 30 ± 10 and 24 ± 6 min ($P < 0.05$). We conclude that the recovery from rocuronium neuromuscular blockade was longer in Chinese compared with Caucasian patients and in adults compared with children.

(Anesth Analg 2000;91:1526–30)

Table 2. Pharmacodynamic parameters.

	men (n = 121)	women (n = 124)
ONSET TIME (seconds)	104.7 (12.2)	92.5 (14.2)***
CLINICAL DURATION (minutes)	31.3 (5.5)	43.1 (7.9)***
RECOVERY INDEX (minutes)	14.8 (4.0)	14.7 (5.0)

Data are means (SD - standard deviation), ***p < 0.0001




Fig. 2. Onset time in seconds (= time interval from the completion of the intravenous injection of rocuronium to maximal T₁ depression in TOF-stimulation).
Data are medians. The percentage values describe the increase compared to young females.
M = males, F = females, Young = age 20-40 yrs, Elderly = 60-75 yrs




Fig. 3. Clinical duration in minutes (= time interval from the completion of the intravenous injection of rocuronium to spontaneous recovery of T₁ to 25% of the control value in TOF-stimulation).
Data are medians. The percentage values describe the increase compared to young males.
M = males, F = females, Young = age 20-40 yrs, Elderly = 60-75 yrs




Fig. 4. Interval to full recovery in minutes (= interval from the completion of the intravenous injection of rocuronium to spontaneous recovery to TOF-ratio 0.90, which reflects complete recovery from the block).
Data are medians. The percentage values describe the increase compared to young males.
M = males, F = females, Young = age 20-40 yrs, Elderly = 60-75 yrs

TABLE 24-1 COMMON WEIGHT SCALARS

Name	Equations
Ideal body weight	Male: 50 kg + 2.3 kg for each 2.54 cm (1 in) over 152 cm (5 ft) Female: 45.5 kg + 2.3 kg for each 2.54 cm (1 in) over 152 cm (5 ft)
Lean body mass	Male: $1.1 \times \text{TBW} - 128 \times (\text{TBW} \div \text{Ht})^2$ Female: $1.07 \times \text{TBW} - 148 \times (\text{TBW} \div \text{Ht})^2$
Fat free mass ³⁵	Male: $(9.27 \times 10^3 \times \text{TBW}) \div (6.68 \times 10^3 + 216 \times \text{BMI})$ Female: $(9.27 \times 10^3 \times \text{TBW}) \div (8.78 \times 10^3 + 244 \times \text{BMI})$
Pharmacokinetic mass ^{36,37}	$52 \div [1 + (196.4 \times e^{-0.025 \text{ TBW}} - 53.66) \div 100]$ (fentanyl only)
Corrected body weight ^{38,39}	$\text{IBW} + 0.4^* (\text{IBW} - \text{FFM})$

BMI, Body mass index; FFM, fat-free mass; Ht, height in centimeters; IBW, ideal body weight; LBM, lean body mass; MFFM, modified fat-free mass; TBW, total body weight in kg.

*The dose/kg using IBW, TBW, or FFM in an obese person are all less than the dose/kg using TBW in a nonobese patient.

TABLE 24-2 DOSING WEIGHTS BASED ON VARIOUS DOSING SCALARS

Dosing Scalar	176-cm (6-ft) Male	
	68 kg (BMI = 22)	185 kg (BMI = 66)
	Dosing Weight (kg)	Dosing Weight (kg)
Total body weight (TBW)	68	185
Ideal body weight (IBW)	71	71
Lean body mass (LBM)	55	62
Fat-free mass (FFM)	55	87
Corrected body weight (CBW)	68	115

BMI, Body mass index (kg/m²).

Dose adjustment of anaesthetics in the morbidly obese

J. Ingrande and H. J. M. Lemmens*

Department of Anesthesia, Stanford University School of Medicine, 300 Pasteur Drive, Room H3576, Stanford, CA 94305, USA




Fig 1 Relationship of TBW, fat weight, and LBW to BMI in a standard height male. LBW and fat weight were derived from the equations of Janmahasatian *et al.*¹¹

Table 1 Weight-based dosing scalar recommendation for commonly used i.v. anaesthetics. CO, cardiac output; IBW, ideal body weight; LBW, lean body weight; TBW, total body weight

Drug	Dosing scalar	Comments
Thiopental	Induction: LBW Maintenance: TBW	Simulations showed a 60% decrease in peak plasma concentration in MO subjects compared with lean subjects after a 250 mg dose. ²⁶ Induction dose adjusted to LBW results in same peak plasma concentration as dose adjusted to CO. ²⁶ Volumes and clearances increase proportionally with TBW. ²⁵
Propofol	Induction: LBW Maintenance: TBW	MO subjects given an induction dose based on LBW required similar amounts of propofol and similar times to loss of consciousness compared with lean subjects given propofol based on TBW. ²⁹ Volume of distribution and clearance at steady state increases with increasing TBW. ²⁸
Fentanyl	LBW	Clearance increases linearly with 'PK mass', an arbitrary scalar highly correlated to LBW. ⁴⁶
Remifentanyl	LBW	An infusion based on LBW results in similar plasma concentrations as normal weight subjects were given an infusion based on TBW. ⁵¹
Succinylcholine	TBW	Administration of 1 mg kg ⁻¹ based on TBW resulted in a more profound block and better intubating conditions compared with doses based on IBW or LBW. ⁶⁷
Vecuronium	IBW	Doses based on TBW result in a prolonged duration of action in obese vs non-obese subjects. ^{69 70}
Rocuronium	IBW	There is an increased duration of action when the drug is given based on TBW vs IBW. ⁷¹
Atracurium, Cisatracurium	IBW	The duration of action is prolonged in obese subjects when given on the basis of TBW vs IBW. ^{73 74}




Figure 1. Temporary decrease in train-of-four (TOF) ratio and T1 during reversal of rocuronium-induced muscle relaxation (0.9 mg/kg) with sugammadex (0.5 mg/kg administered 42 min after rocuronium). At the time of sugammadex administration the posttetanic-count (PTC) value was 1.




Figure 2. Observed train-of-four (TOF) data (+) and the results of simulations (solid lines) of various sugammadex dosing amounts. Muscle relaxation rebound only occurs for sugammadex doses in a limited range. The simulations indicate that for this patient, doses larger than about 1 mg/kg are sufficient to achieve rapid muscle relaxation reversal and avoid muscle relaxation rebound.

Eleveld DJ et al. Anesth Analg 2007;104:582-4



Deep block	Dose
If spontaneous recovery of the twitch response has reached 1-2 PTCs, no twitch responses to TOF	4 mg/kg

Moderate block	Dose
If spontaneous recovery has reached the reappearance of the second twitch (T ₂) in response to TOF stimulation	2 mg/kg




Fig. 4. Predicted probabilities of postoperative pulmonary complications in different age groups in orthopaedic, gynaecological, and major abdominal surgery with a duration of anaesthesia of less than 200 min. The full lines represent patients having residual neuromuscular block (TOF < 0.70) following the use of pancuronium, the broken lines patients with TOF \geq 0.70 following pancuronium and all atracurium and vecuronium patients, independent of the TOF ratio at end of anaesthesia (see text for further explanation).

Berg H et al. *Acta Anaesthesiol Scand.* 1997 Oct;41(9):1095-1103

Table 5

Comparison between patients with and without POPC. Median values and 25th–75th percentiles are given.


	Patients without POPC (n=644)	Patients with POPC (n=46)	Significance level P
Age in years	51.6 (38–66)	65.0 (56–76)	0.000011
Duration of anaesthesia	150 (115–190)	193 (160–230)	0.000027
Duration of surgery	92 (65–130)	121 (90–165)	0.00028
Central temperature at end of anaesthesia (°C)	36.0 (35.6–36.5)	35.7 (35.2–36.2)	0.00084



Medication Error

The Swiss Cheese Model

Originator: Reason

High Reliability Organizations (HROs) deploy "Independent Redundancies"






Cantineau et al. Anesthesiology. 1994;81(3):585-590.

CO NENÍ INDIKOVANÉ,
JE KONTRAINDIKOVANÉ!






Nástup anestezie:
propofol 1.5 - 2 µg/kg



Nástup analgezie:
sufentanil 0.4 µg/kg



Nástup relaxace:
rocuronium 1 mg/kg

OBYČEJNÁ ANESTEZIE



DOBŘÁ ANESTEZIE